Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
10/2001
10/31/2001EP1148902A1 Method of enhancing needleless transdermal powdered drug delivery
10/31/2001EP1044201A4 3-substituted adenines via2-thioxanthines
10/31/2001EP0787131B1 Benzenesulphonamide derivatives as bradykinine antagonists
10/31/2001EP0760649B1 Fluticasone propionate formulations
10/31/2001DE10020813A1 Verwendung von N2-substituierten Benz[f]indazol-4,9-chinonen als Antiparasitika Use of N2-substituted benz [f] indazole-4,9-quinones as antiparasitic
10/31/2001DE10020812A1 Verwendung von Naphthindazol-4,9-chinonen als Antiparasitika Use of Naphthindazol-4,9-quinones as antiparasitic
10/31/2001DE10020505A1 RSV NS Proteine antagonisieren die Interferon (IFN) Antwort RSV NS proteins antagonize the interferon (IFN) response
10/31/2001DE10019252A1 Polydesoxyribonukleotide zur Hemmung der ICAM-1-Genexpression Polydeoxyribonucleotides to inhibit the ICAM-1 gene expression
10/31/2001DE10019136A1 Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung Polyamide nucleic acid derivatives, means, and methods for their preparation
10/31/2001DE10019135A1 Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung Polyamide nucleic acid derivatives, means, and methods for their preparation
10/31/2001CN1320116A Heterocyclic 2-substituted ketoamides useful for treating hair loss in mammals
10/31/2001CN1320035A Antibiotic compositions for treatment of the eye, ear and nose
10/31/2001CN1319420A Medicine for treating asthma
10/31/2001CN1073988C Substituted N-heteroaroylguanidin, preparation, pharmaceutical application and medicine containg same
10/30/2001US6310217 Antiinflammatory and analgesic agents
10/30/2001US6310205 Intermediates for preparing 3-substituted adenines and 3,8-di-substituted 6-aminopurine derivatives for use as phosphodiesterase inhibitors.
10/30/2001US6310092 Treating systemic lupus, multiple sclerosis, rheumatoid arthritis, septic shock, erythema nodosum leprosy, septicemia, uveitis, adult respiratory distress syndrome or inflammatory bowel disease
10/30/2001US6310079 Non-steroidal antiinflammatory agents
10/30/2001US6310065 Pyridazinone hydrochloride compound and method for producing the same
10/30/2001US6309671 Stable glassy state powder formulations
10/30/2001US6309663 Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
10/30/2001US6309651 A method of inhibiting, moderating or diagnosing pseudomonas aeruginosa infection is disclosed.
10/30/2001US6309623 Plurality of perforated microstructures having a mean aerodynamic diameter of less than 5 mum and comprising at least one bioactive agent wherein said suspension medium comprises at least one propellant
10/30/2001CA2084669C [3h,7h]thiazolo[3,4-a]pyridines with antiasthmatic and a antiinflammatory actions on the respiratory tract
10/25/2001WO2001083485A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives
10/25/2001WO2001079487A2 Polydesoxyribonucleotides for inhibiting the expression of the icam-1-gene
10/25/2001WO2001079480A1 Albumin fusion proteins
10/25/2001WO2001079478A1 Factors participating in degranulation of mast cells, dnas encoding the same, method of screening inhibitors of these factors and the inhibitors
10/25/2001WO2001079444A2 Albumin fusion proteins
10/25/2001WO2001079443A2 Albumin fusion proteins
10/25/2001WO2001079442A2 Albumin fusion proteins
10/25/2001WO2001079288A2 Cytokine uses; compositions; methods
10/25/2001WO2001079282A2 Molecules associated with human reproduction
10/25/2001WO2001079271A1 Albumin fusion proteins
10/25/2001WO2001079258A1 Albumin fusion proteins
10/25/2001WO2001079249A2 Peptide nucleic acid derivatives with a negative charge, agents and methods for producing them
10/25/2001WO2001079216A2 Polyamide nucleic acid derivatives, agents and methods for producing them
10/25/2001WO2001079173A2 Enamine derivatives as cell adhesion molecules
10/25/2001WO2001079164A2 N-substituted dithiocarbamates for the treatment of biological disorders
10/25/2001WO2001079156A1 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001WO2001079155A2 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
10/25/2001WO2001078894A2 Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
10/25/2001WO2001078782A1 Single-dose antihistamine/decongestant formulations for treating rhinitis
10/25/2001WO2001078779A2 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
10/25/2001WO2001078768A2 Targeted vaccine delivery systems
10/25/2001WO2001078754A2 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
10/25/2001WO2001078746A1 Respiratory compositions
10/25/2001WO2001078743A1 Medical combinations comprising tiotropium and mometasone
10/25/2001WO2001078742A1 Medical combination comprising salmeterol and budesonide
10/25/2001WO2001078741A1 Medical combinations comprising tiotropium and budesonide
10/25/2001WO2001078740A1 Medical combinations comprising mometasone and salmeterol
10/25/2001WO2001078739A1 Medical combinations comprising tiotropium and fluticasone proprionate
10/25/2001WO2001078738A1 Medical compositions comprising (r,r)-formoterol and rofleponide
10/25/2001WO2001078737A1 Medical combinations comprising formoterol and budesonide
10/25/2001WO2001078736A1 Medical combinations comprising tiotropium and rofleponide
10/25/2001WO2001078735A1 Medicaments for treating respiratory disorders comprising formoterol and fluticasone
10/25/2001WO2001078734A1 Methods of treatment
10/25/2001WO2001078719A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001WO2001078697A2 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
10/25/2001WO2001078696A2 Formulations for use in inhaler devices
10/25/2001WO2001078695A2 Pharmaceutical formulations for dry powder inhalers
10/25/2001WO2001078694A2 Formulations for use in inhaler devices
10/25/2001WO2001078693A2 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
10/25/2001WO2001078654A2 Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001WO2001078533A2 Nutritional modules
10/25/2001WO2001028987A8 Benzylcycloalkyl amines as modulators of chemokine receptor activity
10/25/2001WO2001027113A3 PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES
10/25/2001WO2001027099A3 Bicyclic compounds composition and method for stabilizing the same
10/25/2001WO2001025238A3 Heterocyclic compounds useful as inhibitors of tyrosine kinases
10/25/2001WO2001012790A3 Isomerase proteins
10/25/2001WO2000061541A8 Pharmaceutical compounds
10/25/2001US20010034349 Methods of hydrating mucosal surfaces
10/25/2001US20010034348 Nitric oxide synthase inhibitor; nervous system disorders
10/25/2001US20010034340 Hormone replacement therapy
10/25/2001US20010034339 For eyes, ears or noses
10/25/2001US20010034331 Isolated polypeptide
10/25/2001US20010034062 For engineering cells for delivery of antibodies to combat respiratory diseases, viral infection, asthma, allergy, and macular degeneration
10/25/2001US20010032643 Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage
10/25/2001DE10019062A1 Use of known and new 2-guanidino-4-aryl-quinazoline derivatives as NHE-3 inhibitors useful for the treatment of e.g. hypertension, thrombosis, cardiac ischemia, peripheral and CNS ischemia
10/25/2001CA2747325A1 Albumin fusion proteins
10/25/2001CA2407531A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives
10/25/2001CA2406378A1 Targeted vaccine delivery systems
10/25/2001CA2406245A1 Il-174 uses, compositions and methods
10/25/2001CA2406220A1 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
10/25/2001CA2405709A1 Albumin fusion proteins
10/25/2001CA2405701A1 Albumin fusion proteins
10/25/2001CA2405684A1 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
10/25/2001CA2405599A1 Medicaments for treating respiratory disorders comprising formoterol and fluticasone
10/25/2001CA2405597A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001CA2405563A1 Albumin fusion proteins
10/25/2001CA2405557A1 Albumin fusion proteins
10/25/2001CA2405550A1 Albumin fusion proteins
10/25/2001CA2405525A1 Albumin fusion proteins
10/25/2001CA2405451A1 Molecules associated with human reproduction
10/25/2001CA2405377A1 Nutritional modules
10/25/2001CA2405238A1 Single-dose antihistamine/decongestant formulations for treating rhinitis
10/25/2001CA2405233A1 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
10/25/2001CA2405078A1 Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
10/25/2001CA2403490A1 N-substituted dithiocarbamates for the treatment of biological disorders
10/24/2001EP1148059A1 Thiazolopyrimidine compounds, process for the preparation of the same and uses thereof
1 ... 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 ... 878